NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading TWST? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround situation. The company is currently loss-making, and while it has stable management, its recent financial performance has been weak, making the outlook uncertain.
The market currently reflects a justified valuation, with a low expectations gap. However, there is a premium compared to peers, indicating that some positive outcomes may already be priced in.
Management aims to achieve adjusted EBITDA breakeven by Q4 FY26, but they are currently behind on this goal. Revenue guidance has been raised, and recent growth indicates some progress, although gross margin performance is mixed.
The long-term thesis hinges on the company's ability to meet its financial targets and the performance of sector bellwethers like TMO, DHR, and IDXX. Any negative guidance or earnings misses from these companies could impact TWST's trajectory.
In the next 1 to 3 years, TWST's performance will depend on its execution against management's goals and external sector conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The revenue guidance has been raised to $442-$447 million for FY26, indicating positive growth potential. Additionally, the launch of a new product aligns with the company's growth objectives.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: This report will provide insights into revenue, margins, and overall performance. It can shift investor sentiment.
Confirms one read:Earnings report shows revenue growth and positive margin trends.
Confirms the other:Earnings report reveals a decline in revenue or margins.
Why it matters: Strong revenue growth supports the raised guidance and shows business momentum.
Confirms:Q3 FY26 revenue reported at $110M or higher.
Disproves:Q3 FY26 revenue falls below $100M, indicating weak performance.
Why it matters: Confirming revenue guidance shows the company is on track for growth. It affects investor confidence.
Confirms:Q3 FY26 revenue reported between $442M and $447M, confirming guidance.
Disproves:Q3 FY26 revenue falls below $442M, indicating a miss on guidance.
Why it matters: This guidance is key to confirming continued growth momentum. It shows if the company can sustain its revenue trajectory.
Confirms:Q3 revenue is expected to be between $114 million and $115 million. This shows steady growth.
Disproves:Guidance is below $114 million. This points to possible revenue problems.
Why it matters: If health care revenue growth speeds up, it may help Twist Bioscience. This could improve investor sentiment.
Confirms:Health care revenue growth is speeding up again. It may reach 10% or more.
Disproves:Health care revenue growth continues to slow below 10%.
Why it matters: Breaking even would be a big step for the company. It shows they can make money.
Confirms:Adjusted EBITDA for Q4 FY26 is breakeven. This shows they are improving operations.
Disproves:Adjusted EBITDA is still negative. This shows they have ongoing problems with operations.
Why it matters: Keeping gross margin above 52% is key. It helps with financial health and investor trust.
Confirms:Gross margin is above 52%. This shows good cost control and strong pricing power.
Disproves:Gross margin falls below 52%, raising concerns about cost control and pricing.
